Prognostic factors for pN2 non-small cell lung cancer: a comprehensive evidence from 73 studies involving 23,772 patients*

Author:

Li Shuo,Feng Yanlin,Liang Chunzi,Tu Jiancheng

Abstract

Abstract Obojective Non-small-cell lung cancer (NSCLC) is a common malignancy. pN2 NSCLC, with pathologically confirmed ipsilateral mediastinal/subcarinal nodes metastasis, has been known as a very heterogeneous subgroup in terms of its anatomical, biological and patient characteristics. Prognostic factors based on patient characteristics were not well determined yet in this subgroup, and there is currently no standard treatment recommendation for these heterogeneous pN2 subjects. Apparent disagreements and inconsistency exist in study reports concerning the prognostic significance of certain factors in pN2 NSCLC, especially regarding to the issue about whether skip N2 metastasis benefit from surgery. Methods We therefore performed this comprehensive summary of the published literatures to draw a more precise and less uncertain conclusion. After a comprehensive literature search, a total of 73 studies involving 23,773 subjects were included according to eligibility criteria. Results As expected, most of the investigated factors, such as old age, male, advanced pathological T stage, advanced clinical N stage, multiple N2 stations, extended surgical resection (pneumonectomy), and incomplete resection, but not post-operation treatment (eg. chemotherapy and radiotherapy) were significantly associated with poor survival. However, skip N2 metastasis was favourable prognostic factors in operable pN2 NSCLC subjects. Other factors (histological type and primary tumour side) were neutral in terms of association with overall survival. We highlighted a number of important prognostic factors for pN2 NSCLC patients. Particularly, patients with skip N2 disease benefit from surgery. Conclusion Our findings could be used as reference information for decision-making in clinical practice and future study design.

Publisher

Ovid Technologies (Wolters Kluwer Health)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3